Risankizumab shows faster response in bio naïve than in bio‐experienced psoriatic patients
2022; Wiley; Volume: 36; Issue: 10 Linguagem: Inglês
10.1111/jdv.18314
ISSN1468-3083
AutoresLuca Mastorino, Franco Castelli, Elena Stroppiana, Anna Verrone, Michela Ortoncelli, Sara Susca, Sara Boskovic, S.G. Passerini, Nicole Macagno, Caterina Cariti, M. Licciardello, C. Solaroli, G. Pertusi, M.G. Aragone, G. Baggini, C. Addese, C. Leporati, R. Peila, M.T. Giura, Gianluca Rossotto, Paolo Pella, L. Mocci, Giulia Merlo, R. Tiberio, F. Graziola, Pietro Quaglino, Paolo Dapavo, Simone Ribero,
Tópico(s)Autoimmune Bullous Skin Diseases
ResumoJournal of the European Academy of Dermatology and VenereologyVolume 36, Issue 10 p. e838-e841 Letter to the Editor Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients L. Mastorino, Corresponding Author L. Mastorino [email protected] orcid.org/0000-0001-7386-3219 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalyCorrespondence: L. Mastorino. E-mail: [email protected]Search for more papers by this authorF. Castelli, F. Castelli Section of Dermatology, Koelliker Hospital, Turin, ItalySearch for more papers by this authorE. Stroppiana, E. Stroppiana Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorA. Verrone, A. Verrone Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorM. Ortoncelli, M. Ortoncelli Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorS. Susca, S. Susca Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorS. Boskovic, S. Boskovic Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorS.G. Passerini, S.G. Passerini Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorN. Macagno, N. Macagno orcid.org/0000-0002-0097-2139 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorC. Cariti, C. Cariti Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorM. Licciardello, M. Licciardello Section of Dermatology, Koelliker Hospital, Turin, ItalySearch for more papers by this authorC. Solaroli, C. Solaroli Section of Dermatology, Koelliker Hospital, Turin, ItalySearch for more papers by this authorG. Pertusi, G. Pertusi Outpatient Clinic, Section of Dermatology, ASL VC, Vercelli, ItalySearch for more papers by this authorM.G. Aragone, M.G. Aragone Outpatient Clinic, Section of Dermatology, ASL AL, Alessandria, ItalySearch for more papers by this authorG. Baggini, G. Baggini Outpatient Clinic, Section of Dermatology, ASL AL, Alessandria, ItalySearch for more papers by this authorC. Addese, C. Addese Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, ItalySearch for more papers by this authorC. Leporati, C. Leporati Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, ItalySearch for more papers by this authorR. Peila, R. Peila Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, ItalySearch for more papers by this authorM.T. Giura, M.T. Giura Surgery Department, Section of Dermatology, Cardinal Massaia Hospital, ASL AT, Asti, ItalySearch for more papers by this authorG. Rossotto, G. Rossotto Surgery Department, Section of Dermatology, Cardinal Massaia Hospital, ASL AT, Asti, ItalySearch for more papers by this authorP. Pella, P. Pella Oncology Department, Section of Dermatology, Degli Infermi Hospital, ASL BI, Biella, ItalySearch for more papers by this authorL. Mocci, L. Mocci Section of Dermatology, AO AL Santi Antonio e Biagio e Cesare Arrigo, Alessandria, ItalySearch for more papers by this authorG. Merlo, G. Merlo Section of Dermatology, AO AL Santi Antonio e Biagio e Cesare Arrigo, Alessandria, ItalySearch for more papers by this authorR. Tiberio, R. Tiberio Dermatologic Clinic, AOU Maggiore della Carità Hospital, Novara, ItalySearch for more papers by this authorF. Graziola, F. Graziola Dermatologic Clinic, AOU Maggiore della Carità Hospital, Novara, ItalySearch for more papers by this authorP. Quaglino, P. Quaglino orcid.org/0000-0003-4185-9586 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy Share last authorship.Search for more papers by this authorP. Dapavo, P. Dapavo Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy Share last authorship.Search for more papers by this authorS. Ribero, S. Ribero orcid.org/0000-0002-0098-1406 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy Share last authorship.Search for more papers by this author L. Mastorino, Corresponding Author L. Mastorino [email protected] orcid.org/0000-0001-7386-3219 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalyCorrespondence: L. Mastorino. E-mail: [email protected]Search for more papers by this authorF. Castelli, F. Castelli Section of Dermatology, Koelliker Hospital, Turin, ItalySearch for more papers by this authorE. Stroppiana, E. Stroppiana Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorA. Verrone, A. Verrone Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorM. Ortoncelli, M. Ortoncelli Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorS. Susca, S. Susca Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorS. Boskovic, S. Boskovic Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorS.G. Passerini, S.G. Passerini Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorN. Macagno, N. Macagno orcid.org/0000-0002-0097-2139 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorC. Cariti, C. Cariti Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, ItalySearch for more papers by this authorM. Licciardello, M. Licciardello Section of Dermatology, Koelliker Hospital, Turin, ItalySearch for more papers by this authorC. Solaroli, C. Solaroli Section of Dermatology, Koelliker Hospital, Turin, ItalySearch for more papers by this authorG. Pertusi, G. Pertusi Outpatient Clinic, Section of Dermatology, ASL VC, Vercelli, ItalySearch for more papers by this authorM.G. Aragone, M.G. Aragone Outpatient Clinic, Section of Dermatology, ASL AL, Alessandria, ItalySearch for more papers by this authorG. Baggini, G. Baggini Outpatient Clinic, Section of Dermatology, ASL AL, Alessandria, ItalySearch for more papers by this authorC. Addese, C. Addese Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, ItalySearch for more papers by this authorC. Leporati, C. Leporati Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, ItalySearch for more papers by this authorR. Peila, R. Peila Outpatient Clinic, Section of Dermatology, ASLTO4, Ivrea, ItalySearch for more papers by this authorM.T. Giura, M.T. Giura Surgery Department, Section of Dermatology, Cardinal Massaia Hospital, ASL AT, Asti, ItalySearch for more papers by this authorG. Rossotto, G. Rossotto Surgery Department, Section of Dermatology, Cardinal Massaia Hospital, ASL AT, Asti, ItalySearch for more papers by this authorP. Pella, P. Pella Oncology Department, Section of Dermatology, Degli Infermi Hospital, ASL BI, Biella, ItalySearch for more papers by this authorL. Mocci, L. Mocci Section of Dermatology, AO AL Santi Antonio e Biagio e Cesare Arrigo, Alessandria, ItalySearch for more papers by this authorG. Merlo, G. Merlo Section of Dermatology, AO AL Santi Antonio e Biagio e Cesare Arrigo, Alessandria, ItalySearch for more papers by this authorR. Tiberio, R. Tiberio Dermatologic Clinic, AOU Maggiore della Carità Hospital, Novara, ItalySearch for more papers by this authorF. Graziola, F. Graziola Dermatologic Clinic, AOU Maggiore della Carità Hospital, Novara, ItalySearch for more papers by this authorP. Quaglino, P. Quaglino orcid.org/0000-0003-4185-9586 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy Share last authorship.Search for more papers by this authorP. Dapavo, P. Dapavo Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy Share last authorship.Search for more papers by this authorS. Ribero, S. Ribero orcid.org/0000-0002-0098-1406 Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy Share last authorship.Search for more papers by this author First published: 10 June 2022 https://doi.org/10.1111/jdv.18314Citations: 5 Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Mastorino L, Sara S, Megna M et al. Risankizumab shows high efficacy and Maintenance in improvement of response until week 52. Dermatol Ther 2022; 14: e15378. Google Scholar 2Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–661. 10.1016/S0140-6736(18)31713-6 CASPubMedWeb of Science®Google Scholar 3Warren RB, Blauvelt A, Poulin Y et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol 2021; 184: 50–59. 10.1111/bjd.19341 CASPubMedWeb of Science®Google Scholar 4Gkalpakiotis S, Cetkovska P, Arenberger P et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from The Czech Republic. Dermatol Ther (Heidelb) 2021; 11: 1345–1355. 10.1007/s13555-021-00556-2 PubMedWeb of Science®Google Scholar 5Megna M, Cinelli E, Gallo L, Camela E, Ruggiero A, Fabbrocini G. Risankizumab in real life: preliminary results of efficacy and safety in psoriasis during a 16-week period. Arch Dermatol Res 2022; 314: 619–623. 10.1007/s00403-021-02200-7 CASPubMedWeb of Science®Google Scholar 6Hansel K, Zangrilli A, Bianchi L et al. A 52-week update of a multicentre real-life experience on effectiveness and safety of Risankizumab in psoriasis. J Eur Acad Dermatol Venereol 2021; 35: e169–e170. 10.1111/jdv.17003 CASPubMedWeb of Science®Google Scholar 7Borroni RG, Malagoli P, Gargiulo L et al. Real-life effectiveness and safety of Risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol 2021; 101: adv00605. 10.2340/actadv.v101.283 CASPubMedWeb of Science®Google Scholar 8Augustin M, Lambert J, Zema C et al. Effect of Risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol 2020; 156: 1344–1353. 10.1001/jamadermatol.2020.3617 PubMedWeb of Science®Google Scholar 9Dawoud NM, El Badawy MB, Al Eid HS, Abdel Fattah MM. Risankizumab effectiveness and safety in psoriasis patients who failed other biologics: real-life case series. Indian J Dermatol Venereol Leprol 2021; 88: 1–6. https://doi.org/10.25259/IJDVL_510_2021 10.25259/IJDVL_510_2021 PubMedWeb of Science®Google Scholar 10Mastorino L, Roccuzzo G, Dapavo P et al. Patients with psoriasis resistant to multiple biologic therapies: characteristics and definition of a difficult-to-treat population. Br J Dermatol 2022; 187: 263–265. 10.1111/bjd.21048 PubMedWeb of Science®Google Scholar Citing Literature Volume36, Issue10October 2022Pages e838-e841 ReferencesRelatedInformation
Referência(s)